Plerixafor - the magic bullet in stem cell mobilization failure?

Leukemia Research

Volumn 35, Issue 6, 2011, Pages 701-702

  Worel, Nina ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Lymphoma; Plerixafor; Stem cell mobilization failure

Indexed keywords

GRANULOCYTE COLONY STIMULATING FACTOR; PLACEBO; PLERIXAFOR;

APHERESIS; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; DRUG EFFICACY; EDITORIAL; GASTROINTESTINAL DISEASE; HODGKIN DISEASE; HUMAN; INJECTION SITE REACTION; MULTIPLE MYELOMA; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; RISK FACTOR; SINGLE DRUG DOSE; STEM CELL MOBILIZATION;

FEMALE; GRANULOCYTE COLONY-STIMULATING FACTOR; HEMATOPOIETIC STEM CELL MOBILIZATION; HETEROCYCLIC COMPOUNDS; HUMANS; LYMPHOMA; MALE; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION;

EID: 79955610370     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2011.02.003     Document Type: Editorial

References (7)

1. Arcaini L., Laszlo D., Rizzi S., Balzarotti M., Antoniazzi F., Ruggero V., et al. Plerixafor and G-CSF for PBSC mobilization in patients with lymphoma who failed previous attempts with G-CSF and chemotherapy: a REL (Rete Ematologica Lombarda) experience. Leuk Res 2011, 35:712-714.
2. Pusic I., Jiang S.Y., Landua S., Uy G.L., Rettig M.P., Cashen A.F., et al. Impact of mobilization and remobilization strategies on achieving sufficient stem cell yields for autologous transplantation. Biol Blood Marrow Transplant 2008, 14:1045-1056.
3. Flomenberg N., Devine S.M., Dipersio J.F., Liesveld J.L., McCarty J.M., Rowley S.D., et al. The use of AMD3100 plus G-CSF for autologous hematopoietic progenitor cell mobilization is superior to G-CSF alone. Blood 2005, 106:1867-1874.
4. DiPersio J.F., Micallef I.N., Stiff P.J., Bolwell B.J., Maziarz R.T., Jacobsen E., et al. 3101 investigators. Phase III prospective randomized double-blind placebo-controlled trial of plerixafor plus granulocyte colony-stimulating factor compared with placebo plus granulocyte colony-stimulating factor for autologous stem-cell mobilization and transplantation for patients with non-Hodgkin's lymphoma. J Clin Oncol 2009, 27(October (1)):4767-4773.
5. DiPersio J.F., Stadtmauer E.A., Nademanee A., Micallef I.N., Stiff P.J., Kaufman J.L., et al. 3102 investigators. Plerixafor and G-CSF versus placebo and G-CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma. Blood 2009, 113:5720-5726.
6. Calandra G., McCarty J., McGuirk J., Tricot G., Crocker S.A., Badel K., et al. AMD3100 plus G-CSF can successfully mobilize CD34+ cells from non-Hodgkin's lymphoma, Hodgkin's disease and multiple myeloma patients previously failing mobilization with chemotherapy and/or cytokine treatment: compassionate use data. Bone Marrow Transplant. 2008, 41:331-338.
7. D'Addio A., Curti A., Worel N., Douglas K., Motta M.R., Rizzi S., et al. The addition of plerixafor is safe and allows adequate PBSC collection in multiple myeloma and lymphoma patients poor mobilizers after chemotherapy and G-CSF. Bone Marrow Transplant 2010, [May 31] [Epub ahead of print].